We are live on ! Find out more
ADMS

Adamas Pharmaceuticals
ADMS

Delisted

ADMS was delisted on the 23rd of November, 2021.

Back to rankings

52 hedge funds and large institutions have $196M invested in Adamas Pharmaceuticals in 2014 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 21 increasing their positions, 7 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

208% more capital invested

Capital invested by funds: $63.7M → $196M (+$133M)

200% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 7

150% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 6

18% more funds holding

Funds holding: 44 → 52 (+8)

Holders
52
Holders Change
+8
Holders Change %
+18.18%
% of All Funds
1.39%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.05%
New
15
Increased
21
Reduced
7
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$7.11M
2
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$2.75M
3
GPP
Great Point Partners
Connecticut
+$2.59M
4
TC
TFS Capital
Pennsylvania
+$1.34M
5
EA
Emerald Advisers
Pennsylvania
+$1.21M

Top Sellers

Rank Fund Capital Flow
1
BS
Bow Street
New York
-$1.65M
2
BA
BlackRock Advisors
Delaware
-$1.46M
3
BG
BlackRock Group
United Kingdom
-$890K
4
BlackRock
BlackRock
New York
-$393K
5
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$241K
Name Holding Trade Value Shares
Change 		Change in
Stake
BIT
26
BlackRock Institutional Trust
California
$417K -$9.88K -651 -3%
State Street
27
State Street
Massachusetts
$410K +$14.6K +961 +4%
GCP
28
GSA Capital Partners
United Kingdom
$317K +$78.7K +5,186 +40%
CSS
29
Cubist Systematic Strategies
Connecticut
$302K +$264K +17,415 New
B
30
Barings
North Carolina
$254K +$66.8K +4,400 +43%
RFC
31
Russell Frank Company
Washington
$232K +$204K +13,438 New
GS
32
Gagnon Securities
New York
$216K -$531 -35 -0.3%
Millennium Management
33
Millennium Management
New York
$213K +$186K +12,255 New
Deutsche Bank
34
Deutsche Bank
Germany
$210K +$124K +8,187 +207%
Goldman Sachs
35
Goldman Sachs
New York
$201K -$36.7K -2,421 -17%
TCIM
36
TIAA CREF Investment Management
New York
$165K -$1.18K -78 -0.8%
BIM
37
BlackRock Investment Management
Delaware
$148K – – –
California State Teachers Retirement System (CalSTRS)
38
California State Teachers Retirement System (CalSTRS)
California
$93K +$349 +23 +0.4%
TA
39
Teachers Advisors
New York
$72K – – –
NFA
40
Nationwide Fund Advisors
Ohio
$38K – – –
TRCT
41
Tower Research Capital (TRC)
New York
$34K +$30.1K +1,983 New
AIG
42
American International Group
New York
$31.9K -$1.12K -74 -4%
Citigroup
43
Citigroup
New York
$26K +$21K +1,387 +1,334%
BA
44
BlackRock Advisors
Delaware
$20K -$1.46M -96,300 -99%
Bank of America
45
Bank of America
North Carolina
$14K +$12.1K +800 New
UBS Group
46
UBS Group
Switzerland
$10K +$8.95K +590 New
AllianceBernstein
47
AllianceBernstein
Tennessee
$7K – – –
Barclays
48
Barclays
United Kingdom
$4K +$3.14K +207 +690%
DA
49
Denali Advisors
California
$2K – – –
Wells Fargo
50
Wells Fargo
California
$2K +$15 +1 +0.7%
1
2
3

ADMS Hedge Fund Activity: Q4 2014 in Review

52 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in Adamas Pharmaceuticals (ADMS) for Q4 2014, worth a combined $196M — up 208% from $63.7M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new ADMS positions and 6 closed out — a net gain of 9 holders — while 21 added to existing stakes and 7 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $7.11M. The largest seller was Bow Street, exiting entirely with an estimated $1.65M sold.

  • 52 institutional investors held Adamas Pharmaceuticals (ADMS) as of Q4 2014, up from 44 in Q3 2014.
  • Funds reported $196M of Adamas Pharmaceuticals stock for Q4 2014, up 208% quarter-over-quarter.
  • 15 funds opened new Adamas Pharmaceuticals positions in Q4 2014 and 6 closed out, a net change of +9 holders.
  • The largest Adamas Pharmaceuticals buyer in Q4 2014 was Fidelity Investments, an estimated $7.11M added.
  • The largest Adamas Pharmaceuticals seller in Q4 2014 was Bow Street, an estimated $1.65M sold.

Based on aggregated 13F filings for Q4 2014.